CA9 and neoplasm: However, most low-molecular-weight CA-IX-targeted radioligands are rapidly cleared from blood by glomerular filtration in the kidney, and show insufficient tumor retention or marked renal uptake of radioactivity (9–12), which may compromise tumor contrast in the process of diagnosis and increase the risk of nephrotoxicity in therapy.